None

Osimertinib (Osimertinib) is an anti-tumor agent and a third-generation receptor tyrosine kinase inhibitor. Once marketed, osimertinib can be used as an adjuvant treatment after tumor resection for patients with non-small cell lung cancer who carry epidermal growth factor receptor (EGFR) exon 19 deletion (del19) or exon 21 (L858R) substitution mutations (detected by a U.S. Food and Drug Administration-approved diagnostic test).

Osimertinib is also indicated for the first-line treatment of metastatic NSCLC harboring EGFR exon 19 deletion (del19) or exon 21 (L858R) substitution mutations (as detected by an FDA-approved diagnostic test); and in patients harboring EGFR who experience disease progression during or after treatment with an EGFR tyrosine kinase inhibitor. T790M-mutated metastatic non-small cell lung cancer (detected by an FDA-approved diagnostic test). Designated as an orphan drug by the U.S. Food and Drug Administration for the treatment of EGFR mutation-positive non-small cell lung cancer.

OsimertinibThe original drug has been marketed in China and has entered the scope of Class B medical insurance through the relevant regulations of the National Medical Insurance Bureau, but it is only reimbursed for patients who meet the above indications. SpecificationThe price of 80mg*30 tablets per box may be around 5,000 yuan, which is relatively expensive. Currently available overseas Osimertinib generics, such as the specifications produced by Bangladesh Pharmaceutical FactoryThe price of each box of 80mg*30 tablets may be more than 800 yuan (the price may fluctuate due to exchange rate effects), which is relatively cheap. Osimertinib generics have basically the same pharmaceutical ingredients as the original drugs sold domestically and abroad. For more drug information and specific prices, please consult Yaode Medical Consultant.